Angiotensin III (human, mouse): Mechanisms and Benchmarks for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a biologically active hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe) derived from angiotensin II via N-terminal cleavage and is a key effector within the renin-angiotensin-aldosterone system (RAAS) (Oliveira et al., 2025). It retains full aldosterone-stimulating capability and mediates ~40% of the pressor activity of angiotensin II (APExBIO A1043). Angiotensin III interacts with both AT1 and AT2 receptors, with notable selectivity for AT2 signaling. Experimental data confirm its use in rodent models for inducing pressor and dipsogenic responses, supporting cardiovascular and neuroendocrine research (related review). The peptide is supplied as a solid, is highly soluble in water, ethanol, and DMSO, and should be stored at -20°C desiccated for stability.

Biological Rationale

Angiotensin III is a naturally occurring hexapeptide fragment (Arg-Val-Tyr-Ile-His-Pro-Phe) produced from the N-terminal cleavage of angiotensin II by angiotensinases in erythrocytes and tissues (Oliveira et al., 2025). It forms an integral part of the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that regulates blood pressure, fluid balance, and electrolyte homeostasis. The RAAS pathway initiates with the cleavage of angiotensinogen by renin to form angiotensin I, which is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II is further processed to generate angiotensin III, which exerts distinct biological effects (APExBIO A1043).

Angiotensin III is present in both human and rodent tissues, including brain, kidney, and vascular endothelium. It contributes to cardiovascular homeostasis by modulating vasoconstriction and stimulating aldosterone release from the adrenal cortex. Its molecular weight is 931.09 g/mol, and the chemical formula is C₄₆H₆₆N₁₂O₉ (APExBIO A1043).

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III binds both AT1 and AT2 receptor subtypes, which are G protein-coupled receptors (GPCRs) expressed in various tissues. While AT1 receptor activation mediates vasoconstriction and sodium retention, AT2 receptor signaling is associated with vasodilation and anti-fibrotic effects (Oliveira et al., 2025). Angiotensin III displays relative specificity for the AT2 receptor compared to angiotensin II, making it a valuable probe for dissecting receptor subtype functions. Upon binding to these receptors, angiotensin III activates intracellular signaling cascades that lead to increased aldosterone synthesis and suppression of renin release.

In experimental rodent models, exogenous administration of angiotensin III induces pressor responses (increased blood pressure) and dipsogenic activity (stimulation of thirst) (Molecular Insights review). These effects parallel those of angiotensin II but with distinct receptor contributions and tissue distributions. Notably, angiotensin III is the primary endogenous peptide responsible for aldosterone secretion under certain physiological conditions (APExBIO A1043).

Evidence & Benchmarks

• Angiotensin III (2–8) is generated from angiotensin II (1–8) via N-terminal cleavage by aminopeptidases, and its structure has been confirmed by mass spectrometry and sequencing (Oliveira et al., 2025, Figure 1).
• Angiotensin III mediates approximately 40% of the pressor activity of angiotensin II, as measured in rat arterial pressure assays (APExBIO A1043).
• It retains full aldosterone-stimulating activity in adrenal cell cultures compared to angiotensin II at equimolar concentrations (Oliveira et al., 2025, Table 2).
• Angiotensin III shows higher affinity for AT2 than AT1 receptors in radioligand binding assays, with a Ki in the sub-micromolar range (Oliveira et al., 2025).
• Exogenous angiotensin III suppresses renin release in perfused kidney preparations, indicating negative feedback on the RAAS axis (APExBIO A1043).
• Solubility data: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, ≥93.1 mg/mL in DMSO at room temperature (20–25°C) (APExBIO A1043).

This article updates and extends the mechanistic focus presented in "Angiotensin III (human, mouse): Molecular Insights & Next..." by providing quantitative benchmarks and solubility parameters relevant for experimental design. For troubleshooting and advanced workflows, see "Angiotensin III: Applied Workflows for Cardiovascular & N...", which details protocol optimization beyond standard references.

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is widely used as a tool compound in cardiovascular, hypertension, and neuroendocrine research. Its dual receptor activity enables mechanistic studies of AT1 and AT2 signaling. It is especially valuable for dissecting aldosterone secretion and blood pressure regulation in experimental models. The peptide is also used to investigate the impact of RAAS peptides on viral pathogenesis, including SARS-CoV-2 spike protein interactions (Oliveira et al., 2025).

However, it should not be assumed that angiotensin III acts identically to angiotensin II in all tissues or disease models. Differences in receptor expression, tissue distribution, and degradation pathways can result in distinct physiological responses. For a translational perspective, the article "Angiotensin III: Unleashing Translational Innovation in C..." discusses strategic deployment in disease modeling, complementing this technical overview.

Common Pitfalls or Misconceptions

• Assuming angiotensin III and angiotensin II are functionally identical in all assay systems; differences in receptor selectivity and tissue effects exist.
• Using angiotensin III for chronic in vivo administration without stability controls; the peptide is susceptible to proteolytic degradation and should be freshly prepared.
• Expecting direct antagonism of AT1 receptor-mediated effects; angiotensin III can activate both AT1 and AT2 receptors, but with distinct efficacy.
• Neglecting storage conditions: peptide solutions are not recommended for long-term storage—solid form at -20°C is required for stability.
• Assuming all RAAS peptides enhance SARS-CoV-2 spike-AXL binding equally; angiotensin III has unique N-terminal structure influencing this activity (see Oliveira et al., 2025).

Workflow Integration & Parameters

Preparation: Angiotensin III (human, mouse) is supplied as a lyophilized solid by APExBIO (SKU: A1043). Reconstitute in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), or DMSO (≥93.1 mg/mL) at room temperature (20–25°C). Avoid repeated freeze-thaw cycles and prepare aliquots for single use. Store reconstituted solutions at 4°C for short-term experiments (≤24 h) and discard unused portions.

Experimental Use: For in vitro assays, concentrations typically range from 10 nM to 10 μM depending on cell type and endpoint. For in vivo rodent studies, dosing regimens should be optimized based on pilot titration, starting from 0.1–10 μg/kg body weight. Control for protease activity in biological samples to prevent degradation.

Quality Control: The peptide identity and purity are confirmed by HPLC and mass spectrometry. Ensure experimental controls include vehicle and, where relevant, angiotensin II comparators.

For optimized cardiovascular and neuroendocrine workflows—including troubleshooting strategies—see "Angiotensin III: Optimizing Cardiovascular and Neuroendoc...", which provides stepwise protocols and advanced assay designs.

Conclusion & Outlook

Angiotensin III (human, mouse) is a potent, well-characterized RAAS peptide with distinct applications in cardiovascular and neuroendocrine research. Its dual receptor profile, robust solubility, and validated activity benchmarks make it an indispensable tool for mechanistic and translational studies. Ongoing research is expanding its utility into models of viral pathogenesis and receptor signaling. For further product specifications and ordering, refer to the APExBIO product page.